In addition, Reininger et al. (16) reported higher number of tacrolimus dose adjustments in kidney transplant recipients who were extensive and intermediate CYP3A5 metabolizers, and Chen et al. (17) recommended an optimal initial regimen of tacrolimus for children with systemic lupus erythematosus based on the CYP3A5 polymorphism. This evidence concerns the gene CYP3A5 and systemic lupus erythematosus.